The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Advice for community oncologists preparing to administer their first bispecific antibody therapy
In this video, Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, shares advice for community oncologists preparing to administer their first bispecific antibody therapy. She encourages them to feel empowered and have confidence in their ability to administer these agents, while also reminding them that they can reach out for help when needed. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You can do it. You know, I think we all don’t know what we don’t know, right? And when you go back to think of a lot of the therapies that we’ve done over the years, whether it’s been rituximab for the first time or obinutuzumab for the first time, it was all scary. Patients react to these drugs. I mean, there are even chemotherapy drugs that people can have significant reactions to...
You can do it. You know, I think we all don’t know what we don’t know, right? And when you go back to think of a lot of the therapies that we’ve done over the years, whether it’s been rituximab for the first time or obinutuzumab for the first time, it was all scary. Patients react to these drugs. I mean, there are even chemotherapy drugs that people can have significant reactions to. And we all do those now like it’s old hat. So it’s scary at first, but I don’t think that any community doctor should feel they can’t do this. I think they should almost be empowered to do it. The bispecifics are here to stay. And what we’re seeing is it’s not just in the malignant hematology space, but it’s across the board, you know, it’s completely across all cancer, all solid tumors, more autoimmune diseases. So, you know, these patients are in the community and they deserve to be able to stay in their own beds without having to travel to an academic center two hours away, you know, for step-up dosing. So I just, I think knowing that, you know, trust the process, you can do it and just never be afraid to reach out for help.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: AbbVie, ADC Therapeutics, AstraZeneca, BMS, Beigene, Janssen, Genentech, Gilead/Kite, Pfizer; Advisory Board: AbbVie, Adaptive Biotechnologies, AstraZeneca, BMS, Beigene, Genmab, Incyte, Lilly; Steering committee: AbbVie, Genmab; Speaker fees: AbbVie, Beigene, Genmab.
